MedKoo product information:

 Pipobroman

Pipobroman was approved in German. Pipobroman is an antineoplastic agent. Specifically it is a piperazine derivative with a chemical structure close to that of many DNA alkylating agents. Pipobroman has well documented clinical activity against polycythemia vera and essential thrombocythemia. According to drugbank, pipobroman was indicated for the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.

The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.

  1: Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L. Polycythemia vera. Intern Emerg Med. 2010 Mar 16. [Epub ahead of print] PubMed PMID: 20237866.

2: Fabris F, Randi ML. Essential thrombocythemia: past and present. Intern Emerg Med. 2009 Oct;4(5):381-8. Epub 2009 Jul 28. PubMed PMID: 19636672.

3: Sobottka A, Lehmann P. [Confluent indurated facial nodules and pustules in a 55-year-old man]. Hautarzt. 2008 Sep;59(9):734-6. German. PubMed PMID: 18615248.

4: Tsamaloukas AG. Pipobroman gets regulatory approval outside Germany. Dtsch Arztebl Int. 2008 Jan;105(4):71-2; author reply 72. Epub 2008 Jan 25. PubMed PMID: 19633773; PubMed Central PMCID: PMC2696734.

5: Hafiji J, Majmudar V, Mathews S, Green A, Rytina E, Burrows NP. A case of bromoderma and bromism. Br J Dermatol. 2008 Feb;158(2):427-9. Epub 2007 Nov 28. PubMed PMID: 18047506.

6: Reilly JT. Practical approach to treating essential thrombocythaemia: case studies. Eur J Haematol Suppl. 2007 Oct;(68):40-2. PubMed PMID: 17727566.

7: Tchen T, Durlach A, Bernard P, Grange F. [Multiples squamous cell carcinomas during treatment with pipobroman]. Ann Dermatol Venereol. 2007 Jun-Jul;134(6-7):570-1. French. PubMed PMID: 17657187.

8: McMullin MF. A review of the therapeutic agents used in the management of polycythaemia vera. Hematol Oncol. 2007 Jun;25(2):58-65. Review. PubMed PMID: 17352450.

9: Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):417-21. Review. PubMed PMID: 16810617.

10: Herry A, Douet-Guilbert N, Guéganic N, Morel F, Le Bris MJ, Berthou C, De Braekeleer M. Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. Ann Hematol. 2006 Apr;85(4):244-9. Epub 2006 Jan 20. PubMed PMID: 16425025.

11: Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T; ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005 Apr 1;105(7):2664-70. Epub 2004 Dec 7. PubMed PMID: 15585653.

12: Passamonti F, Cazzola M. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. Haematologica. 2004 Nov;89(11):1284. PubMed PMID: 15531447.

13: Orlandi E, Bernasconi P, Boni M, Calatroni S, Lazzarino M. Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset. Ann Hematol. 2005 Feb;84(2):127-8. Epub 2004 Sep 15. PubMed PMID: 15378276.

14: Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, Pascutto C, Cazzola M, Lazzarino M. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol. 2004 Aug;83(8):495-7. Epub 2004 Jun 3. PubMed PMID: 15175894.

15: De Sanctis V, Mazzucconi MG, Spadea A, Alfò M, Mancini M, Bizzoni L, Peraino M, Mandelli F. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol. 2003 Nov;123(3):517-21. PubMed PMID: 14617017.

16: Passamonti F, Lazzarino M. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003 Sep;44(9):1483-8. Review. PubMed PMID: 14565648.

17: Polycythemia vera. Hematol Oncol Clin North Am. 2003 Oct;17(5):1191-210. Review. Erratum in: Hematol Oncol Clin North Am. 2004 Feb;18(1):xv. Berlin Nathanial I [corrected to Berlin Nathaniel]. PubMed PMID: 14560782.

18: Griesshammer M, Langer C. Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert Opin Pharmacother. 2003 Sep;4(9):1499-505. Review. PubMed PMID: 12943479.

19: Barbui T, Finazzi G. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Curr Hematol Rep. 2003 May;2(3):248-56. Review. PubMed PMID: 12901347.

20: Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003;4(3):198-207. PubMed PMID: 12764352.

21: Sironi M, Bertola G, Lodato A, Spinelli M, Sciariada L. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. Acta Haematol. 2003;109(3):161-2. PubMed PMID: 12714827.

22: Rain JD. [Polycythemia vera]. Rev Prat. 2002 Oct 15;52(16):1801-7. Review. French. PubMed PMID: 12564173.

23: Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003 Jan;88(1):13-8. PubMed PMID: 12551821.

24: Barbui T. What is the standard treatment in essential thrombocythemia. Int J Hematol. 2002 Aug;76 Suppl 2:311-7. Review. PubMed PMID: 12430943.

25: Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, Volpe G, Pistorio A, Giardini I, Rocca B, Caresana M, Lazzarino M, Bernasconi C. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia. 2002 Oct;16(10):2078-83. PubMed PMID: 12357360.

26: Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, Baratè C, Canevari A, Corso A, Bernasconi P, Cazzola M, Lazzarino M. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol. 2002 Mar;116(4):855-61. PubMed PMID: 11886392.

27: Triffet A, Straetmans N, Ferrant A. Bone marrow aplasia after pipobroman: an immune-mediated mechanism? Br J Haematol. 2001 Dec;115(3):713-4. Review. PubMed PMID: 11736962.

28: Estève E, Georgescu V, Heitzmann P, Martin L. [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. Ann Dermatol Venereol. 2001 Sep;128(8-9):919-21. French. PubMed PMID: 11590345.

29: Najean Y, Rain JD, Lejeune F, Echard M, Fermand JP, Gruyer P, Brahimi S. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age]. Ann Med Interne (Paris). 1998 Mar;149(2):94-100. French. PubMed PMID: 11490531.

30: Griesshammer M, Bangerter M, Grünewald M. Current treatment practice for essential thrombocythaemia in adults. Expert Opin Pharmacother. 2001 Mar;2(3):385-93. Review. PubMed PMID: 11336593.

31: Briere J, Guilmin F. Management of patients with essential thrombocythemia: current concepts and perspectives. Pathol Biol (Paris). 2001 Mar;49(2):178-83. Review. PubMed PMID: 11317966.

32: Rain JD. [Hydroxyurea--is it a harmless drug in Vaquez disease?]]. Pathol Biol (Paris). 2001 Mar;49(2):158-63. French. PubMed PMID: 11317962.

33: Lengfelder E, Hehlmann R. [Polycythemia vera: current status of therapy]. Dtsch Med Wochenschr. 2000 Oct 13;125(41):1243-7. Review. German. PubMed PMID: 11076265.

34: Passamonti F, Brusamolino E, Lazzarino M, Baraté C, Klersy C, Orlandi E, Canevari A, Castelli G, Merante S, Bernasconi C. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000 Oct;85(10):1011-8. PubMed PMID: 11025590.

35: Pazart L, Carpentier F, Durocher A, Mougeot C, Najean Y, Godeau P. Impact of the consensus conference on polycythemia vera. An opportunity to change or a sign of change? Int J Technol Assess Health Care. 1999 Summer;15(3):602-7. Review. PubMed PMID: 10874386.

36: Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma. 2000 Apr;37(3-4):379-85. PubMed PMID: 10752989.

37: Tefferi A, Silverstein MN. Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol. 1998 Dec;11(4):769-85. Review. PubMed PMID: 10640216.

38: Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents. Haematologica. 1999 Nov;84(11):1049-50. PubMed PMID: 10553169.

39: Bouscary D, Jondeau K, Viguié F, Zompi S, Fontenay-Roupie M, Quarre MC, Vassilief D, Dreyfus F, Casadevall N. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera. Leuk Lymphoma. 1999 May;33(5-6):607-11. PubMed PMID: 10342591.

40: Bauters F. [Vaquez disease. Diagnosis, course, treatment]. Rev Prat. 1998 Sep 1;48(13):1483-9. Review. French. PubMed PMID: 10050634.

41: Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, Fenaux P. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999 Feb;13(2):250-7. PubMed PMID: 10025899.

42: Heis N, Rintelen C, Gisslinger B, Knöbl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999 Jan;62(1):27-31. PubMed PMID: 9918308.

43: Pearson TC, Green AR, Reilly JT, Harrisoni G. Leukemic transformation in polycythemia Vera. MPD(UK) Study Group. Blood. 1998 Sep 1;92(5):1837-8. PubMed PMID: 9716616.

44: Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia? Blood. 1998 Aug 15;92(4):1459-60; author reply 1460-1. PubMed PMID: 9694740.

45: Petti MC, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E, Cosenza M, Malagnino F. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia. 1998 Jun;12(6):869-74. PubMed PMID: 9639413.

46: Gabriel Botella F, Labiós Gómez M, Sempere Montés J, Nicolau Arrufat A, Martínez Silvestre M, Vayá Montaña A. [Primary polycythaemia vera in the elderly]. An Med Interna. 1998 Jan;15(1):21-4. Spanish. PubMed PMID: 9580177.

47: Sterkers Y, Preudhomme C, Laï JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998 Jan 15;91(2):616-22. PubMed PMID: 9427717.

48: Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997 Nov 1;90(9):3370-7. PubMed PMID: 9345019.

49: Sánchez Fayos J, Román Barbero A, Nevado Reviriego I. [Efficacious treatment of a fatal blood disease: polycythemia vera]. Sangre (Barc). 1997 Jun;42(3):215-8. Review. Spanish. PubMed PMID: 9381264.

50: Sánchez Fayos J, Prieto E, Román A, Soto de Ozaeta C, Nevado I, Richart A, Chica E, Loscertales J, Calabuig T, Benítez J, Outeiriño J. [Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases]. Sangre (Barc). 1996 Dec;41(6):447-57. Review. Spanish. PubMed PMID: 9148422.

51: Arai Y, Masuda M, Okamura T, Wada M, Motoji T, Mizoguchi H. [Polycythemia vera progressing to acute lymphoblastic leukemia after 13 years]. Rinsho Ketsueki. 1996 Dec;37(12):1405-9. Review. Japanese. PubMed PMID: 8997130.

52: Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk Lymphoma. 1996 Sep;22 Suppl 1:149-60. Review. PubMed PMID: 8951786.

53: Najean Y, Rain JD, Dresch C, Goguel A, Lejeune F, Echard M, Grange MJ. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Leuk Lymphoma. 1996 Sep;22 Suppl 1:111-9. Review. PubMed PMID: 8951781.

54: Sagripanti A, Ferretti A, Nicolini A, Carpi A. Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders. Biomed Pharmacother. 1996;50(8):376-82. PubMed PMID: 8952859.

55: Messora C, Bensi L, Vanzanelli P, Temperani P, Carotenuto M, Sacchi S. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman. Haematologica. 1996 Jan-Feb;81(1):51-3. PubMed PMID: 8900853.

56: Paitel JF, Trechot P, Stockemer V, Dorvaux V, Lederlin P. [Acute liver disease during treatment with pipobroman and allopurinol]. Presse Med. 1995 Mar 4;24(9):460. French. PubMed PMID: 7746823.

57: Cornu P. [Long-term hematological management of cyanotic congenital heart diseases]. Arch Mal Coeur Vaiss. 1994 Nov;87(11):1413-20. French. PubMed PMID: 7771887.

58: Rain JD. Clinical and laboratory assessment and therapeutic problems in longstanding polycythaemia vera. Nouv Rev Fr Hematol. 1994 Apr;36(2):197-203. PubMed PMID: 8036142.

59: Fuse I. [Recent trends in therapy of chronic myeloproliferative disorders]. Nippon Naika Gakkai Zasshi. 1993 Jul 10;82(7):1058-62. Japanese. PubMed PMID: 7693834.

60: Boivin P. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol. 1993;35(5):491-8. PubMed PMID: 8295823.

61: Najean Y. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies]. Presse Med. 1992 Nov 7;21(37):1753-7. French. PubMed PMID: 1488420.

62: Boivin P, Bernard JF. Polycythaemia and hyperparathyroidism: a fortuitous association? Eur J Haematol. 1992 Sep;49(3):153-5. PubMed PMID: 1446733.

63: Hino K, Sato S, Sakashita A, Tomoyasu S, Tsuruoka N, Koike T. [Megakaryoblastic transformation associated with disseminated intravascular coagulation in the course of polycythemia vera: a case report]. Rinsho Ketsueki. 1992 Apr;33(4):500-6. Review. Japanese. PubMed PMID: 1602615.

64: Najean Y, Dresch C, Rain JD. Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. The French Group for the Study of Polycythemias. Nouv Rev Fr Hematol. 1991;33(2):201-3. PubMed PMID: 1766854.

65: Chistolini A, Mazzucconi MG, Ferrari A, la Verde G, Ferrazza G, Dragoni F, Vitale A, Arcieri R, Mandelli F. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica. 1990 Nov-Dec;75(6):537-40. Review. PubMed PMID: 2098295.

66: Ferrari A, Mazzucconi MG, Martinelli E, Giona F, Paesano R, Pachi A. Pregnancy in a young woman affected by essential thrombocythemia: a case report. Haematologica. 1989 Jan-Feb;74(1):115-6. PubMed PMID: 2498176.

67: Bauters F, Jouet JP, Simon M, Pollet JP, Fenaux P, Walter MP. [Efficacy of pipobroman in the treatment of essential thrombocythemia]. Presse Med. 1988 Jan 23;17(2):81. French. PubMed PMID: 2964031.

68: Mazzucconi MG, Francesconi M, Chistolini A, Falcione E, Ferrari A, Tirindelli MC, Mandelli F. Pipobroman therapy of essential thrombocythemia. Scand J Haematol. 1986 Oct;37(4):306-9. PubMed PMID: 3787181.

69: Brusamolino E, Canevari A, Salvaneschi L, Merante S, Bernasconi C. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat Rep. 1984 Nov;68(11):1339-42. PubMed PMID: 6541969.

70: Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol. 1984 Jun;2(6):558-61. PubMed PMID: 6374054.

71: Perreau-Boutet MC, Najman A, Stachowiak J, Parlier Y, Gorin NC, Duhamel G. [Management of polycythaemia with pipobroman]. Nouv Presse Med. 1982 Sep 4;11(34):2549-53. French. PubMed PMID: 7133977.

72: Najman A, Stachowiak J, Parlier Y, Gorin NC, Duhamel G. Pipobroman therapy of polycythemia vera. Blood. 1982 May;59(5):890-4. PubMed PMID: 7074217.

73: Juncá Piera J, Durán Suárez JR, Triginer Boixeda J. [Osteolytic lesions in chronic myeloid leukemia. Report of three cases (author's transl)]. Med Clin (Barc). 1981 Mar 25;76(6):259-61. Spanish. PubMed PMID: 6942204.

74: Graczyk J, Kowalczyk K, Pakulska W, Szadowska A. [Effect of selected piperazine derivatives on the metabolic clearance rate of idoxuridine-I-125 in mice with transplanted leukemia L1210]. Acta Pol Pharm. 1981;38(6):717-21. Polish. PubMed PMID: 7348532.

75: Graczyk J, Pakulska W, Groszkowski S, Najman L. [Antineoplastic activity in mice of 4,4'-(2-methyl-1,4-piperazinodiyl)bis-(4-oxo)-propenyl-1-carboxylic-1 acid diethyl ester]. Acta Pol Pharm. 1980;37(2):249-54. Polish. PubMed PMID: 7468274.

76: Seino Y, Nagao M, Yahagi T, Hoshi A, Kawachi T, Sugimura T. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA100, and TA92. Cancer Res. 1978 Jul;38(7):2148-56. PubMed PMID: 350383.

77: Andrzejewska-Golec E, Broda B, Najman L. [Effects of pipobroman and other piperazine derivatives on mitotic activity and nucleic acids of root meristems of wheat (Triticum aestivum L.) II. Biochemical studies]. Acta Pol Pharm. 1977;34(5):539-42. Polish. PubMed PMID: 602799.

78: Andrzejewska-Golec E, Broda B, Najman L. [Effects of pipobroman and other piperazine derivatives on mitotic activity and nucleic acids of root meristems of wheat (Triticum aestivum L.) I. Cytological studies]. Acta Pol Pharm. 1977;34(5):531-8. Polish. PubMed PMID: 602798.

79: Bauters F, Jouet JP, Goudemand M. [Little known treatment of primary polycythemia: pipobroman (apropos of 19 cases)]. Lille Med. 1976 Mar;21(3):202-8. French. PubMed PMID: 950881.

80: Zsigmond EK, Kothary SP. [Effect of pibobroman on human plasma cholinesterase activity in vitro]. Anesth Analg (Paris). 1975 Mar-Apr;32(2):167-9. French. PubMed PMID: 1229916.

81: Jamshidi K, Ansari A, Windschitl HE, Swaim WR. Primary thrombocythemia. Geriatrics. 1973 Jan;28(1):121-33. PubMed PMID: 4539498.

82: Hermanský F. [Clinical evaluation of antineoplastic agents]. Cas Lek Cesk. 1972 Nov 3;111(45):1067-8. Czech. PubMed PMID: 5084862.

83: Fábryová L, Hrubisko M. [Vercyte in the therapy of polycythemia]. Vnitr Lek. 1972 Nov;18(11):1113-6. Slovak. PubMed PMID: 4634660.

84: Greenwald ES. Cancer chemotherapy. II. N Y State J Med. 1972 Nov 1;72(21):2641-54. Review. PubMed PMID: 4117677.

85: Miyazaki T, Ishizaki T, Maekawa I, Sano H, Idaka K. [Clinical trial of pipobroman (N,N'-bis-(3-bromopropionyl) piperazine) in eight patients with polycythemia vera]. Rinsho Ketsueki. 1972 Oct;13(5):777-86. Japanese. PubMed PMID: 4674853.

86: Kanzawa F, Hoshi A, Kuretani K. Antitumor activity of haloacetylphenothiazines against ascites sarcoma-180. Gann. 1972 Apr;63(2):225-9. PubMed PMID: 4627100.

87: Yellin TO. Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. PubMed PMID: 5556760.

88: Bignotti G, Visca U, Confalonieri C. [Pipobroman in the treatment of some cases of polycythemia vera]. Haematologica. 1971;56(3):157-62. Italian. PubMed PMID: 5003588.

89: Seidenglanz G. [Chemotherapy of malignant tumors. 44]. Pharm Prax. 1970;6:122-38. Review. German. PubMed PMID: 4917035.

90: Vallée G, Boivin P, Dormont J, Soulier JP. [Present treatment of the Vaquez's disease]. Presse Med. 1969 Mar 22;77(14):517-9. French. PubMed PMID: 5783371.

91: Tardiff RG, Dubois KP. Inhibition of hepatic microsomal enzymes by alkylating agents. Arch Int Pharmacodyn Ther. 1969 Feb;177(2):445-56. PubMed PMID: 5807177.

92: Brichta G, Reimer EE, Stoiber T. [Chronic myelosis. Clinical picture and therapy]. Wien Z Inn Med. 1969;50(6):249-57. German. PubMed PMID: 5266008.

93: Drugs in the treatment of leukemia. Br Med J. 1968 Nov 2;4(5626):305-7. PubMed PMID: 5246597; PubMed Central PMCID: PMC1912259.

94: Bilski-Pasquier G, Blanc CM, Bousser J. [Treatment of Vaquez's polycythemia with 1-4, bis-3-bromopropionyl-piperazine. Study of 36 cases]. Presse Med. 1968 Oct 26;76(41):1953-6. French. PubMed PMID: 5248051.

95: Böhnel J, Stacher A. [On the effect of a new cytostatic drug in chronic myeloses and polycythemias]. Wien Med Wochenschr. 1968 Sep 14;118(37):721-3. German. PubMed PMID: 5248360.

96: Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine. JAMA. 1967 May 15;200(7):619-20. PubMed PMID: 5228673.

97: Pipobroman (Vercyte) - a new antineoplastic drug. Med Lett Drugs Ther. 1967 Apr 7;9(7):27. PubMed PMID: 5298493.